MOTE Therapeutics

What MOTE Therapeutics does

MOTE Therapeutics is a preclinical-stage biotechnology company developing a targeted delivery platform for next-generation RNA medicines, with a particular focus on circular RNA (circRNA). The company's core technology is the proprietary mobilize™ (MOTE BIfunctional LocalIZEr) platform — a modular, chemistry-free system that uses non-covalent surface functionalization of lipid nanoparticles (LNPs) to achieve extrahepatic, cell-type-specific RNA delivery. By combining hepatic de-targeting with precision ligand engineering, the platform addresses the central bottleneck in RNA therapeutics: delivering payloads beyond the liver to tissues such as T cells, hematopoietic stem cells, and CNS cells.

The pipeline is organized around three primary target classes: T cells (with a disclosed lead in systemic lupus erythematosus), hematopoietic stem cells (undisclosed indication), and CNS tissues (undisclosed indication). In addition, a June 2026 co-development agreement with affiliated partner Fapon Biopharma added a dual-platform B-cell immunotherapy franchise targeting CD19 and BCMA, comprising a T-cell engager (FPE024) and an in vivo CAR-T therapy (MTX001), with first-in-human and IND milestones targeted for Q4 2026 and Q1 2027 respectively. The company has no commercial products and does not yet generate product revenue.

MOTE is a privately held US-incorporated (Delaware) company with principal operations in Lexington, Massachusetts and an additional office in Dongguan, China. It is a member of the Fapon Group conglomerate, with Fapon Biotech serving as financial backer and Fapon Biopharma as a co-development partner. The company was founded in 2024 by circular RNA pioneer Dr. Alex Wesselhoeft, began operations in July 2024 with a team of 25 scientists, and its business model is oriented around licensing, royalties, and co-development partnerships rather than direct commercialization.

Name

MOTE Therapeutics

Legal name

Mote Therapeutics Inc.

Website

https://motetx.com

Company type

Private

Founded year

2024

Operating status

Operating

Short description

MOTE Therapeutics is a preclinical-stage biotechnology company developing the mobilize™ platform for extrahepatic targeted delivery of circular RNA therapeutics, with pipeline programs in autoimmune (SLE), CNS, and hematological indications and a CD19/BCMA B-cell franchise co-developed with Fapon Biopharma.

Ownership category

akta.pro rank

Product category

RNA Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)

akta.pro secondary industries

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) (HLAAACAC), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)

Keywords

• RNA therapeutics
• Targeted delivery
• Lipid nanoparticles
• Circular RNA medicines
• Extrahepatic delivery

Headquarters

HQ city

Lexington

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. RNA Therapeutics Development: Preclinical-stage company developing targeted RNA nanomedicines. No commercial products yet; revenue model not yet established as programs are in discovery/preclinical stages.

Go-to-market motion1 record

Core offering

MOTE Therapeutics is a preclinical-stage biotechnology company developing next-generation targeted RNA nanomedicines. Its core offering is the proprietary mobilize™ (MOTE BIfunctional LocalIZEr) platform, a modular, scalable, chemistry-free targeted lipid nanoparticle (LNP) delivery system that combines hepatic de-targeting with precision ligand engineering to enable extrahepatic delivery of circular RNA (circRNA) payloads to previously inaccessible cell types and tissues.

Product overview

MOTE Therapeutics is a preclinical-stage biotechnology company offering a single unified platform (mobilize™) that provides targeted RNA delivery technology as its core product. The platform enables modular, scalable, chemistry-free functionalization of LNPs for extrahepatic delivery of RNA payloads, particularly circular RNA (circRNA). The company is building a pipeline of targeted RNA nanomedicines across multiple therapeutic areas including immune cell reprogramming (T cells for SLE), CNS diseases, and hematopoietic stem cell disorders. MOTE operates as a member of Fapon Group with R&D operations in Lexington, MA (USA) and Dongguan, China.

Differentiator

Problem solved

Functional benefit

Brands

• mobilize™: Proprietary targeted LNP delivery platform (MOTE BIfunctional LocalIZEr) for extrahepatic delivery of circRNA, combining hepatic detargeting with cell-specific ligand engineering

Products and services

• mobilize™ Platform (MOTE BIfunctional LocalIZEr) A modular, scalable, chemistry-free targeted lipid nanoparticle (LNP) delivery platform that combines hepatic de-targeting with cell-specific ligand engineering to enable extrahepatic delivery of RNA payloads, including circular RNA (circRNA). A simple inline mixing process tethers recombinant targeting ligands to RNA-containing LNPs for precision in vivo cell reprogramming, eliminating the need for conventional chemical surface functionalization.
• Targeted Lipid Nanoparticles (tLNPs) Proprietary targeted lipid nanoparticles produced via the mobilize™ platform, enabling cell-specific RNA delivery to tissues and cell types beyond the liver for therapeutic applications in autoimmune disease, CNS disorders, and hematological malignancies.
• Circular RNA (circRNA) Delivery Pipeline Pipeline of targeted RNA nanomedicines leveraging the mobilize™ platform for delivery of circular RNA (circRNA) payloads to previously inaccessible cell types, addressing indications including systemic lupus erythematosus (SLE), CNS diseases, and hematopoietic stem cell disorders.

Quantifiable outcome

• Excellent potency demonstrated in NHP studies with tLNP combined with circRNA cargo
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Fapon BiopharmacoreStrategic or Co-development Partner · 19 June 2026Both MOTE and Fapon Biopharma are members of Fapon Group. They are co-developing a dual-platform B-cell immunotherapy franchise targeting CD19 and BCMA with both a T-cell engager (FPE024) and an in vivo CAR-T therapy (MTX001). The companies are pursuing co-development and licensing partnerships together at BIO 2026.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Beam Therapeutics: Beam develops in vivo base-editing and prime-editing therapies, several using LNP delivery to extrahepatic tissues. Its focus on in vivo nucleic acid editing via LNP makes it a strong comparable to MOTE's targeted LNP platform.
• Cartesian Therapeutics: Cartesian develops RNA cell therapies for autoimmune disease, including programs overlapping MOTE's T-cell SLE focus. Comparable because both use RNA engineering to reprogram immune cells, though Cartesian's modality is ex vivo rather than in vivo.
• Verve Therapeutics: Verve is developing in vivo base-editing medicines using LNP delivery to extrahepatic tissues (notably the liver and cardiovascular tissues). It is comparable as a clinical-stage peer tackling the same extrahepatic-delivery problem with LNP-based in vivo nucleic acid therapeutics.
• Capstan Therapeutics: Capstan is developing in vivo cell therapies (including in vivo CAR-T) using targeted LNP delivery of mRNA payloads to immune cells—directly comparable to MOTE's MTX001 in vivo CAR-T program and T-cell SLE program, with overlapping modality and indication space.
• Intellia Therapeutics: Intellia is a clinical-stage in vivo CRISPR/Cas9 company using LNP delivery for extrahepatic indications. It shares MOTE's strategic premise that targeted LNP delivery unlocks in vivo nucleic acid medicines beyond the liver.
• Acuitas Therapeutics: Acuitas is a leading LNP delivery technology company whose ionizable LNPs underpin multiple approved and clinical-stage RNA therapeutics (e.g., Comirnaty, ONPATTRO). It is the most direct comparable to MOTE's mobilize™ platform given shared focus on LNP chemistry and delivery innovation.
• Orna Therapeutics: Orna is a clinical-stage circular RNA (oRNA) therapeutics company developing in vivo therapies using LNP delivery. It is one of the closest direct peers to MOTE given the shared circRNA modality, and the merger with ReNAgade Therapeutics expanded its delivery capabilities into extrahepatic targets.

Broad incumbents

• Alnylam Pharmaceuticals: Alnylam is the established leader in RNA therapeutics (siRNA + GalNAc conjugate delivery to the liver). Comparable as the dominant commercial RNA therapeutics incumbent; MOTE's platform differentiates by pursuing extrahepatic delivery that Alnylam has historically been limited in reaching.
• Moderna: Moderna is the leading mRNA therapeutics and vaccines company, with internal LNP delivery capabilities. Comparable as a broad incumbent in RNA medicines; MOTE's circRNA + extrahepatic positioning differentiates against Moderna's linear mRNA + liver-focused LNP approach.

Emerging players

• Laronde (now part of SalioGen Therapeutics): Laronde was a pioneer in endless RNA (eRNA, a circRNA-like modality) founded by Flagship Pioneering. It is a relevant peer because of the shared circRNA therapeutic modality, though it has been wound down and its assets are now housed within SalioGen.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MOTE Therapeutics